AI-based health screening company iHealthScreen recently announced raising $150,000 in investments on StartEngine. To date, the company has raised $3 million+ in seed and NIH funding combined. 

iHealthScreen presents a unique opportunity to capitalize on AI-driven health screening software developed by medical professionals who are emerging leaders in this multi-billion-dollar market. This integrated, retinal imaging-based system is unprecedented in the surgical robotics industry. 

iHealthScreen is the first company in the world to receive CE certification and Australian and UAE health approvals for age-related macular degeneration (“AMD”), diabetic retinopathy (“DR”) and glaucoma screening. Additionally, hospitals aren’t required for the company’s surgical robotics to be used; its systems can be incorporated into primary care provider facilities at the local level.  

U.S. testing is known to be cost prohibitive for the people that need it most, and primary care providers don't have the resources to do more than basic screenings. This leaves patients without the screening they need and can potentially result in serious health consequences.

iHealthScreen is taking advantage of this problem by developing a fast, easy, accessible and low-cost solution for eye disease screening.

Investment Highlights:

• Raised $750K as seed funding.
• Awarded $2.7M in NIH funding.
• Working on securing additional research grants.
• One U.S. patent (the first patent in late AMD prediction).
• One patent is pending, with four provisional patent applications submitted.
• Existing customers already in place.